aTyr Pharma, Inc.
ATYRNASDAQHealthcare● Active
$0.44
$-0.03(-5.94%)
Market Cap$43348436
P/E Ratio—
52W High$7.29
52W Low$0.395
aTyr Pharma, Inc. (ATYR) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ATYR · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.11
Est. -$0.16 · +31.3%
Revenue
—
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
ATYR reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
$0.09
Rev. $41.31B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.$0.09
Rev. Est.$41.31B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.15 | — | — | — | — | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.16 | -$0.11 | +31.3% | — | — | — |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$0.18 | -$0.14 | +22.2% | — | $0.00B | — |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.20 | -$0.26 | -30.0% | $0.00B | $0.00B | +850.0% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -$0.18 | -$0.22 | -22.2% | — | — | — |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.19 | -$0.17 | +10.5% | — | — | — |
| ▲ Q1 FY2025 | Mar 13, 2025 | -$0.23 | -$0.18 | +21.7% | — | $0.00B | — |
| ▼ Q4 FY2024 | Nov 7, 2024 | -$0.22 | -$0.23 | -4.5% | — | $0.00B | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.15
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.11
EPS Est.
-$0.16
EPS Surpr.
+31.3%
Revenue
—
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$0.14
EPS Est.
-$0.18
EPS Surpr.
+22.2%
Revenue
—
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.26
EPS Est.
-$0.20
EPS Surpr.
-30.0%
Revenue
$0.00B
Q3 FY2025
Aug 7, 2025Miss
EPS Actual
-$0.22
EPS Est.
-$0.18
EPS Surpr.
-22.2%
Revenue
—
Q2 FY2025
May 7, 2025Beat
EPS Actual
-$0.17
EPS Est.
-$0.19
EPS Surpr.
+10.5%
Revenue
—
Q1 FY2025
Mar 13, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.23
EPS Surpr.
+21.7%
Revenue
—
Q4 FY2024
Nov 7, 2024Miss
EPS Actual
-$0.23
EPS Est.
-$0.22
EPS Surpr.
-4.5%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.18 | $-0.18 | $-0.18 | 2 |
| Q3 FY2027 | $-0.18 | $-0.18 | $-0.18 | 1 |
| Q2 FY2027 | $-0.19 | $-0.19 | $-0.19 | 1 |
| Q1 FY2027 | $-0.17 | $-0.17 | $-0.17 | 2 |
| Q4 FY2026 | $-0.16 | $-0.16 | $-0.16 | 2 |
| Q3 FY2026 | $-0.14 | $-0.14 | $-0.13 | 4 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 5 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 0 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +31.3% | $0.56 | $0.50 | -9.98% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +22.2% | $0.96 | $0.90 | -6.45% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -30.0% | $0.81 | $0.77 | -5.35% |
| ▼ Q3 FY2025 | Aug 7, 2025 | -22.2% | $5.34 | $5.24 | -1.87% |
| ▲ Q2 FY2025 | May 7, 2025 | +10.5% | $3.23 | $3.16 | -2.17% |
| ▲ Q1 FY2025 | Mar 13, 2025 | +21.7% | $3.55 | $3.99 | +12.39% |
| ▼ Q4 FY2024 | Nov 7, 2024 | -4.5% | $3.25 | $3.10 | -4.62% |
| ▼ Q3 FY2024 | Aug 13, 2024 | -4.5% | $1.81 | $1.74 | -3.87% |
Q2 FY2026-9.98%
Report Date
May 15, 2026
EPS Beat/Miss
+31.3%
Price Before
$0.56
Price After
$0.50
Q1 FY2026-6.45%
Report Date
Mar 5, 2026
EPS Beat/Miss
+22.2%
Price Before
$0.96
Price After
$0.90
Q4 FY2025-5.35%
Report Date
Nov 6, 2025
EPS Beat/Miss
-30.0%
Price Before
$0.81
Price After
$0.77
Q3 FY2025-1.87%
Report Date
Aug 7, 2025
EPS Beat/Miss
-22.2%
Price Before
$5.34
Price After
$5.24
Q2 FY2025-2.17%
Report Date
May 7, 2025
EPS Beat/Miss
+10.5%
Price Before
$3.23
Price After
$3.16
Q1 FY2025+12.39%
Report Date
Mar 13, 2025
EPS Beat/Miss
+21.7%
Price Before
$3.55
Price After
$3.99
Q4 FY2024-4.62%
Report Date
Nov 7, 2024
EPS Beat/Miss
-4.5%
Price Before
$3.25
Price After
$3.10
Q3 FY2024-3.87%
Report Date
Aug 13, 2024
EPS Beat/Miss
-4.5%
Price Before
$1.81
Price After
$1.74
Avg Beat Reaction-1.55%
Avg Miss Reaction-3.93%
Beat Rate4 / 8 quarters
Largest Move+12.39% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ATYR ends December
aTyr Pharma, Inc. (ATYR) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.11 — beating the analyst consensus of $-0.16 by +31.3%. ATYR has beaten EPS estimates for 2 consecutive quarters. The next ATYR earnings date is expected around September 1, 2026.
Each quarter, investors track ATYR earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ATYR revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ATYR's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ATYR earnings · 5 questionsaTyr Pharma, Inc.'s next earnings report is expected around September 1, 2026. ATYR typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ATYR historically reports after market close (AMC).
ATYR earnings datewhen is ATYR earningsATYR next earnings datewhen does ATYR report earningsATYR earnings calendar
▸ Source: FMP · aTyr Pharma, Inc. SEC filings · US GAAP · aTyr Pharma, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026